Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
Public ClinicalTrials.gov record NCT00300781. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2 Study of HKI-272 In Subjects With Advanced Breast Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn whether neratinib is safe and effective in treating women with advanced human epidermal growth factor receptor 2 (HER2) positive breast cancer.
Study identification
- NCT ID
- NCT00300781
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 136 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 3, 2006
- Primary completion
- Mar 31, 2008
- Completion
- Jan 29, 2018
- Last update posted
- Aug 13, 2018
2006 – 2018
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Colorado Hospital | Aurora | Colorado | 80045 | — |
| Midwestern Regional Medical Center | Zion | Illinois | 60099 | — |
| Louisiana State University | Shreveport | Louisiana | 71103 | — |
| The Cancer Center at GBMC | Baltimore | Maryland | 21204 | — |
| Oncology Care Associates | Bethesda | Maryland | 20817 | — |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02115 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Boston University Medical Center | Boston | Massachusetts | 02118 | — |
| Faulkner Hospital | Boston | Massachusetts | 02130 | — |
| Norris Cotton Cancer Center Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | — |
| The Cancer Institute of New Jersey | New Brunswick | New Jersey | 08901 | — |
| The Cleveland Clinic Taussig Cancer Center | Cleveland | Ohio | 44195 | — |
| Virginia Mason Medical Center | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00300781, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 13, 2018 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00300781 live on ClinicalTrials.gov.